PDF(Pubmed)
Abstract：
Bortezomib (BAN) is a proteasome inhibitor approved for the treatment of multiple myeloma and lymphoma. Despite its efficacy in various tumor models, systemic administration can result in toxicity to healthy organs. The purpose of this study is to evaluate the elution profile of BAN from PMMA cement for the local treatment of orthopedic tumors. BAN solution (5 mg; 2 mg/mL) was mixed with Simplex cement (40 g, Stryker), followed by injection of cement into an antibiotic cement nail mold (13 mm) to coat a 10 mm titanium femoral nail (DePuy Synthes). Once the cement polymerized, the nail was cut into 2 cm segments for the BAN elution study. There is a sustained release of BAN for up to 28 days. The overall concentration of BAN released at each time point was between 74 and 263 ng/ml, which is compatible with the peak blood concentration of a single intravenous BAN injection. This study demonstrates the feasibility of using PMMA bone cement as a local BAN delivery tool, essential for future studies and treatment targeting multiple myeloma cells.
摘要：
硼替佐米（BAN）是一种蛋白酶体抑制剂，已被批准用于治疗多发性骨髓瘤和淋巴瘤。尽管它在各种肿瘤模型中都有疗效，全身给药可导致对健康器官的毒性。这项研究的目的是评估BAN从PMMA骨水泥中的洗脱曲线，用于骨科肿瘤的局部治疗。将BAN溶液（5mg；2mg/mL）与Simplex水泥（40g，Stryker),然后将水泥注入抗生素水泥钉模具（13毫米）以涂覆10毫米钛股骨钉（DePuySynthes）。一旦水泥聚合，将指甲切成2cm段用于BAN洗脱研究。BAN持续释放长达28天。在每个时间点释放的BAN的总浓度在74和263ng/ml之间，这与单次静脉注射BAN的峰值血液浓度相容。这项研究证明了使用PMMA骨水泥作为局部BAN输送工具的可行性，对于针对多发性骨髓瘤细胞的未来研究和治疗至关重要。
